![Most Clinicians Are Still Not Comfortable Sending Chest Pain Patients Home with a Very Low Risk of 30-Day Major Adverse Cardiac Event (MACE) - Journal of Urgent Care Medicine Most Clinicians Are Still Not Comfortable Sending Chest Pain Patients Home with a Very Low Risk of 30-Day Major Adverse Cardiac Event (MACE) - Journal of Urgent Care Medicine](https://www.jucm.com/wp-content/uploads/2021/01/02.21-OR-Figure-1.jpg)
Most Clinicians Are Still Not Comfortable Sending Chest Pain Patients Home with a Very Low Risk of 30-Day Major Adverse Cardiac Event (MACE) - Journal of Urgent Care Medicine
![30-day Major Adverse Cardiac Events (MACE) after elective bariatric surgery: the development and validation of the Bari-MACE clinical predictive tool - ScienceDirect 30-day Major Adverse Cardiac Events (MACE) after elective bariatric surgery: the development and validation of the Bari-MACE clinical predictive tool - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1550728921005888-gr1.jpg)
30-day Major Adverse Cardiac Events (MACE) after elective bariatric surgery: the development and validation of the Bari-MACE clinical predictive tool - ScienceDirect
![Association of Major Adverse Cardiac Events up to 5 Years in Patients With Chest Pain Without Significant Coronary Artery Disease in the Korean Population | Journal of the American Heart Association Association of Major Adverse Cardiac Events up to 5 Years in Patients With Chest Pain Without Significant Coronary Artery Disease in the Korean Population | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/beac94ef-6167-4ca0-bde8-a1e0fcfb986d/jah34185-fig-0002.png)
Association of Major Adverse Cardiac Events up to 5 Years in Patients With Chest Pain Without Significant Coronary Artery Disease in the Korean Population | Journal of the American Heart Association
![Incidence of major adverse cardiovascular events (MACE; includes all-cause death, myocardial infarction, and stroke) between patients in late reduction group and early reduction group. Incidence of major adverse cardiovascular events (MACE; includes all-cause death, myocardial infarction, and stroke) between patients in late reduction group and early reduction group.](https://s3-eu-west-1.amazonaws.com/ppreviews-plos-725668748/2120447/preview.jpg)
Incidence of major adverse cardiovascular events (MACE; includes all-cause death, myocardial infarction, and stroke) between patients in late reduction group and early reduction group.
![A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study | Diabetologia A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study | Diabetologia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00125-021-05556-7/MediaObjects/125_2021_5556_Figa_HTML.png)
A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study | Diabetologia
![Society of Urologic Oncology - COMPARISON OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS WITH ANDROGEN DEPRIVATION THERAPY BY RACE USING REAL-WORLD DATA Society of Urologic Oncology - COMPARISON OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS WITH ANDROGEN DEPRIVATION THERAPY BY RACE USING REAL-WORLD DATA](https://openwaterserverless.azurewebsites.net/api/imageconvert?url=https%3A%2F%2Fvo-general.s3.amazonaws.com%2F58ec95b2-ef6d-442b-b62e-3ccba8548e35%2Faff5cbfd-02d6-48d0-b07d-3f7ddad65f14%3FAWSAccessKeyId%3DAKIAJ4PRWO26HAX3IOCA%26Expires%3D1696692039%26response-content-disposition%3Dinline%253B%2520filename%253D%2522211103-1145-SUO%25202021_MACE%2520by%2520Race%2520Poster-Dr.%2520Twardowski.png%2522%26response-content-type%3Dimage%252Fpng%26Signature%3DxobU2K6QiHCfwF36eLODhBsf7H8%253D&width=640&height=480&color=white)
Society of Urologic Oncology - COMPARISON OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS WITH ANDROGEN DEPRIVATION THERAPY BY RACE USING REAL-WORLD DATA
![Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies | JACC: CardioOncology Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies | JACC: CardioOncology](https://www.jacc.org/cms/asset/508d217a-b6ee-479c-9ff6-97ee0ccadcfc/gr5.jpg)
Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies | JACC: CardioOncology
![Association of Major Adverse Cardiac Events up to 5 Years in Patients With Chest Pain Without Significant Coronary Artery Disease in the Korean Population | Journal of the American Heart Association Association of Major Adverse Cardiac Events up to 5 Years in Patients With Chest Pain Without Significant Coronary Artery Disease in the Korean Population | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/8561b51f-af11-456e-b8b8-662cdbb9f37e/jah34185-fig-0001.png)
Association of Major Adverse Cardiac Events up to 5 Years in Patients With Chest Pain Without Significant Coronary Artery Disease in the Korean Population | Journal of the American Heart Association
![Incidence and Predictors of Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Disease or Multiple Risk Factors | Journal of the American Heart Association Incidence and Predictors of Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Disease or Multiple Risk Factors | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/c01176d0-8532-4916-a996-1ee4efb6dd13/jah34734-fig-0001.png)
Incidence and Predictors of Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Disease or Multiple Risk Factors | Journal of the American Heart Association
![Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib](https://acrabstracts.org/wp-content/uploads/2021/09/ACR_1060309_1.jpg)
Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib
![Two-year major adverse cardiovascular events (MACE) according to the... | Download Scientific Diagram Two-year major adverse cardiovascular events (MACE) according to the... | Download Scientific Diagram](https://www.researchgate.net/publication/236916748/figure/tbl3/AS:202830595006481@1425369990503/Two-year-major-adverse-cardiovascular-events-MACE-according-to-the-use-of-intravascular.png)
Two-year major adverse cardiovascular events (MACE) according to the... | Download Scientific Diagram
![Net adverse clinical events (NACE), major adverse cardiovascular events... | Download Scientific Diagram Net adverse clinical events (NACE), major adverse cardiovascular events... | Download Scientific Diagram](https://www.researchgate.net/publication/322624878/figure/fig2/AS:623650818490370@1525701350736/Net-adverse-clinical-events-NACE-major-adverse-cardiovascular-events-MACE-and.png)
Net adverse clinical events (NACE), major adverse cardiovascular events... | Download Scientific Diagram
![Major adverse cardiac event (MACE) end point frequencies up to 2-year... | Download Scientific Diagram Major adverse cardiac event (MACE) end point frequencies up to 2-year... | Download Scientific Diagram](https://www.researchgate.net/publication/258061948/figure/tbl1/AS:601765124788247@1520483394829/Major-adverse-cardiac-event-MACE-end-point-frequencies-up-to-2-year-follow-up.png)
Major adverse cardiac event (MACE) end point frequencies up to 2-year... | Download Scientific Diagram
![Machine Learning for Prediction of Adverse Cardiovascular Events in Adults With Repaired Tetralogy of Fallot Using Clinical and Cardiovascular Magnetic Resonance Imaging Variables | Circulation: Cardiovascular Imaging Machine Learning for Prediction of Adverse Cardiovascular Events in Adults With Repaired Tetralogy of Fallot Using Clinical and Cardiovascular Magnetic Resonance Imaging Variables | Circulation: Cardiovascular Imaging](https://www.ahajournals.org/cms/asset/7a56fa12-8bb8-473c-b409-2b7081aef6f1/circimaging.122.015205.fig07.jpg)
Machine Learning for Prediction of Adverse Cardiovascular Events in Adults With Repaired Tetralogy of Fallot Using Clinical and Cardiovascular Magnetic Resonance Imaging Variables | Circulation: Cardiovascular Imaging
![PDF) Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review PDF) Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review](https://i1.rgstatic.net/publication/355971662_Major_adverse_cardiovascular_event_definitions_used_in_observational_analysis_of_administrative_databases_a_systematic_review/links/618760cfd7d1af224bc04fbd/largepreview.png)
PDF) Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review
![Risk assessment for major adverse cardiovascular events after noncardiac surgery using self-reported functional capacity: international prospective cohort study - British Journal of Anaesthesia Risk assessment for major adverse cardiovascular events after noncardiac surgery using self-reported functional capacity: international prospective cohort study - British Journal of Anaesthesia](https://www.bjanaesthesia.org.uk/cms/attachment/b5e17752-7857-44ee-9dfb-62dfff710864/gr1_lrg.jpg)
Risk assessment for major adverse cardiovascular events after noncardiac surgery using self-reported functional capacity: international prospective cohort study - British Journal of Anaesthesia
![Reducing Risk of Major Adverse Cardiovascular Events: Role of SGLT2 Inhibitors, GLP-1 Agonists - Endocrinology Advisor Reducing Risk of Major Adverse Cardiovascular Events: Role of SGLT2 Inhibitors, GLP-1 Agonists - Endocrinology Advisor](https://www.endocrinologyadvisor.com/wp-content/uploads/sites/9/2022/07/Table-1.-Trials-of-Cardiovascular-Benefits-of-SGLT2-Inhibitors-1-1024x805.jpg)
Reducing Risk of Major Adverse Cardiovascular Events: Role of SGLT2 Inhibitors, GLP-1 Agonists - Endocrinology Advisor
![Pharmacy | Free Full-Text | Retrospective Study of Appropriate Primary Prevention in Postmenopausal Women Presenting with a Major Adverse Cardiovascular Endpoint (MACE) Pharmacy | Free Full-Text | Retrospective Study of Appropriate Primary Prevention in Postmenopausal Women Presenting with a Major Adverse Cardiovascular Endpoint (MACE)](https://www.mdpi.com/pharmacy/pharmacy-10-00105/article_deploy/html/images/pharmacy-10-00105-g001.png)